Atherosclerosis-related effects of verapamil, anipamil and other calcium antagonists studied on cell culture

  • A. N. Orekhov
  • V. V. Tertov
  • E. M. Pivovarova
  • S. G. Kozlov
  • A. A. Lyakishev
  • M. Ya. Ruda

Abstract

It has been shown that calcium antagonists suppress experimental atherosclerosis in animals (1). Recently it was demonstrated that nifedipine and verapamil suppress the development of human coronary atherosclerosis and induce regression of atherosclerosis in patients (2.3). The mechanisms of antiatherogenic (preventive) and antiatherosclerotic (leading to regression) actions of calcium antagonists remain obscure.

Keywords

Calcium Antagonist Cholesteryl Ester Free Cholesterol Total Protein Synthesis Antiatherosclerotic Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. (1).
    Blumlein S.L., Sievers R., Kidd P., Parmley W.W. (1985). Modification of experimental atherosclerosis by calcium-channel blockers. Am J Cardiol, 55, 165B–171B.CrossRefPubMedGoogle Scholar
  2. (2).
    Kober G., Schneider W., Kaltenbach M. (1989). Can the progression of coronary sclerosis be influenced by calcium antagonists? J Cardiovasc Pharmacol, 13, S2–S6.CrossRefPubMedGoogle Scholar
  3. (3).
    Lichtlen P.R., Hugenhoitz P.G., Rafflenbeul W., INTACT-group (1989). Possible protective effect of nifedipine against progression of atherosclerosis in man (INTACT-study). In: “4th International Symposium on Calcium Antagonists: Pharmacology and CLinical Research. Abstract Book”, Florence (Italy), pp. 127–130.Google Scholar
  4. (4).
    Orekhov A.N., Tertov V.V., Kudryashov S.A. et al. (1986). Primary culture of human aortic intima cells as a model for testing antiatherosclerotic drugs. Effects of cyclic AMP, prostaglandins, calcium antagonists, antioxidants, and lipid-lowering agents. Atherosclerosis, 60, 101–110.CrossRefPubMedGoogle Scholar
  5. (5).
    Orekhov A.N., Tertov V.V., Khashimov Kh.A. et al. (1986). Antiatherosclerotic effects of verapamil in primary culture of human aortic intimal cells. J Hypertension, 4, S153–S155.Google Scholar
  6. (6).
    Orekhov A.N., Tertov V.V., Khashimov Kh.A. et al. (1987). Evidence of antiatherosclerotic action of verapamil from direct effects on arterial cells. Am J Cardiol, 59, 495–496.CrossRefPubMedGoogle Scholar
  7. (7).
    Orekhov A.N., Baldenkov G.N., Tertov V.V, et al. (1988). Cardiovascular drugs and atherosclerosis: effects of calcium antagonists, beta-blockers, and nitrates on atherosclerotic characteristics of human aortic cells. J Cardiovasc Pharmacol, 12, S66–S68.CrossRefPubMedGoogle Scholar
  8. (8).
    Baldenkov G.N., Akopov S.E., Li H.R.. Orekhov A.N. (1988). Prostacyclin, thromboxane A and calcium antagonists: effects on atherosclerotic characteristics of vascular cells. Biomed Biochini Acta, 47, S324–S327.Google Scholar
  9. (9).
    Orekhov A.N., Tertov V.V., Novlkov I.D. et al. (1985). Lipids in cells of atherosclerotic and uninvolved human aorta. I. Lipid composition of aortic tissue and enzyme isolated and cultured cells. Exp Mol Pathol, 42, 117–137.CrossRefPubMedGoogle Scholar
  10. (10).
    Bligh E.G., Dyer W.J. (1959). A rapid method of total lipid extraction and purification. Can J Biochem Physiol, 37, 911–917.CrossRefPubMedGoogle Scholar
  11. (11).
    Dixon W.J., Brown M.B. (1977). Biomedical Computer Programs. P-Series. University of California Press, Berkeley, pp. 185–198.Google Scholar
  12. (12).
    Chazov E.I., Tertov V.V., Orekhov A.N. et al. (1986). Atherogenicity of blood serum from patients with coronary heart disease. Lancet, 2, 595–598.CrossRefPubMedGoogle Scholar
  13. (13).
    Orekhov A.N., Tertov V.V., Pokrovsky S.N. et al. (1988). Blood serum atherogenicity associated with coronary atherosclerosis. Evidence for nonlipid factor providing atherogenicity of low-density lipoproteins and an approach to its elimination. Circ Res, 62, 421–429.PubMedGoogle Scholar
  14. (14).
    Chazov E.I., Orekhov A.N., Tertov V.V. et al. (1988). Atherogenicity of blood plasma from patients with coronary atherosclerosis and its correction. Atherosclerosis Rev, 17, 9–20.Google Scholar
  15. (15).
    Tertov V.V., Orekhov A.N., Martsenyuk O.N. et al. (1989). Low density lipoproteins isolated from the blood of patients with coronary heart disease induce the accumulation of lipids in human aortic cells. Exp Mol Pathol, 50, 337–347.CrossRefPubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1990

Authors and Affiliations

  • A. N. Orekhov
    • 1
  • V. V. Tertov
    • 1
  • E. M. Pivovarova
    • 1
  • S. G. Kozlov
    • 1
  • A. A. Lyakishev
    • 1
  • M. Ya. Ruda
    • 1
  1. 1.USSR Cardiology Research CenterMoscowRussia

Personalised recommendations